Albany Molecular Research (AMRI) Tops Q1 EPS by 1c

Albany Molecular Research (NASDAQ: AMRI) reported Q1 EPS of $0.13, $0.01 better than the analyst estimate of $0.12. Revenue for the quarter came in at $163.8 million versus the consensus estimate of $161.45 million.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• BlackBerry shares gain premarket as Q2 results, guidance beat estimates